scholarly journals HIV‐1 Viral Escape in Cerebrospinal Fluid of Subjects on Suppressive Antiretroviral Treatment

2010 ◽  
Vol 202 (12) ◽  
pp. 1819-1825 ◽  
Author(s):  
Arvid Edén ◽  
Dietmar Fuchs ◽  
Lars Hagberg ◽  
Staffan Nilsson ◽  
Serena Spudich ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Antiretroviral Treatment ◽  
Viral Escape ◽  
Hiv 1

Cerebrospinal Fluid Viral Load in HIV-1-Infected Patients Without Antiretroviral Treatment

1998 ◽  
Vol 17 (4) ◽  
pp. 291-295 ◽  
Author(s):  
Magnus Gisslén ◽  
Lars Hagberg ◽  
Dietmar Fuchs ◽  
Gunnar Norkrans ◽  
Bo Svennerholm
Keyword(s):  
Cerebrospinal Fluid ◽  
Viral Load ◽  
Antiretroviral Treatment ◽  
Hiv 1

scholarly journals Viral and inflammatory markers in cerebrospinal fluid of patients with HIV-1-associated neurocognitive impairment during antiretroviral treatment switch

HIV Medicine ◽  
2015 ◽  
Vol 16 (6) ◽  
pp. 388-392 ◽  
Author(s):  
JM Tiraboschi ◽  
JA Muñoz-Moreno ◽  
MC Puertas ◽  
C Alonso-Villaverde ◽  
A Prats ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Inflammatory Markers ◽  
Antiretroviral Treatment ◽  
Neurocognitive Impairment ◽  
Treatment Switch ◽  
Hiv 1

scholarly journals Asymptomatic Cerebrospinal Fluid HIV-1 Viral Blips and Viral Escape During Antiretroviral Therapy: A Longitudinal Study

2016 ◽  
Vol 214 (12) ◽  
pp. 1822-1825 ◽  
Author(s):  
Arvid Edén ◽  
Staffan Nilsson ◽  
Lars Hagberg ◽  
Dietmar Fuchs ◽  
Henrik Zetterberg ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Longitudinal Study ◽  
Antiretroviral Therapy ◽  
Viral Escape ◽  
Hiv 1

scholarly journals Antiretroviral Treatment Effect on Immune Activation Reduces Cerebrospinal Fluid HIV-1 Infection

2008 ◽  
Vol 47 (5) ◽  
pp. 544-552 ◽  
Author(s):  
Elizabeth Sinclair ◽  
Rollie Ronquillo ◽  
Nicole Lollo ◽  
Steven G Deeks ◽  
Peter Hunt ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Treatment Effect ◽  
Immune Activation ◽  
Antiretroviral Treatment ◽  
Hiv 1

Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?

Aids Reviews ◽  
2017 ◽  
Vol 19 (4) ◽  
Author(s):  
Valentina Svicher ◽  
Giulia Marchetti ◽  
Adrianna Ammassari ◽  
Francesca Ceccherini-Silberstein ◽  
Loredana Sarmati ◽  
...  
Keyword(s):  
Antiretroviral Treatment ◽  
Treatment Success ◽  
Virological Suppression ◽  
Evaluation And Monitoring ◽  
Hiv 1

scholarly journals The Relationships between HIV-1 Infection, History of Methamphetamine Use Disorder, and Soluble Biomarkers in Blood and Cerebrospinal Fluid

Viruses ◽  
2021 ◽  
Vol 13 (7) ◽  
pp. 1287
Author(s):  
T. Walter ◽  
Jennifer Iudicello ◽  
Debra Cookson ◽  
Donald Franklin ◽  
Bin Tang ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Immune System ◽  
Public Health Problem ◽  
Control Group ◽  
Csf Biomarkers ◽  
Immune System Dysfunction ◽  
Immune Biomarkers ◽  
Plasma Factor ◽  
History Of ◽  
Hiv 1

Methamphetamine (METH) use disorder is highly prevalent among people with HIV (PWH) and is a significant public health problem. HIV and METH use are each associated with immune system dysfunction; however, the combined effects on the immune system are poorly understood. This cross-sectional project measured soluble immune biomarkers in plasma and cerebrospinal fluid (CSF) collected from a control group, people with a history of a METH use disorder (METH+), PWH with no history of METH use disorder (HIV+), and PWH with a history of METH use disorder (HIV+/METH+). HIV, METH, and immune dysfunction can also be associated with affective and cognitive deficits, so we characterized mood and cognition in our participants. Two factor analyses were performed for the plasma and CSF biomarkers. Plasma IL-8, Ccl2, VEGF, and 8-isoprostane loaded onto one factor that was highest in the HIV+/METH+ group (p < 0.047) reflecting worse inflammation, vascular injury, and oxidative stress. This plasma factor was also negatively correlated with delayed recall (R = −0.49, p = 0.010), which was worst in the HIV+/METH+ group (p = 0.030 compared to the control group). Overall, these data implicate that combined HIV-1 infection and METH use may exacerbate inflammation, leading to worse cognition.

Sign in / Sign up

Export Citation Format

Share Document